Toronto Dominion Bank Grows Position in Illumina, Inc. (NASDAQ:ILMN)

Toronto Dominion Bank raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 38.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,838 shares of the life sciences company's stock after acquiring an additional 8,578 shares during the quarter. Toronto Dominion Bank's holdings in Illumina were worth $4,022,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Industrial Alliance Investment Management Inc. purchased a new stake in shares of Illumina in the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after buying an additional 168 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Illumina during the 2nd quarter valued at about $61,000. Private Trust Co. NA grew its stake in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after acquiring an additional 212 shares during the period. Finally, Mizuho Securities Co. Ltd. purchased a new stake in Illumina in the 2nd quarter worth approximately $63,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ILMN shares. Leerink Partners lifted their price target on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Piper Sandler dropped their target price on shares of Illumina from $195.00 to $185.00 and set an "overweight" rating for the company in a report on Monday, November 11th. Hsbc Global Res raised Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on Illumina from $125.00 to $140.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Finally, Argus raised Illumina from a "hold" rating to a "buy" rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of "Moderate Buy" and a consensus target price of $165.95.

Illumina Trading Up 0.4 %

ILMN traded up $0.53 during trading on Monday, reaching $144.40. The company had a trading volume of 1,864,291 shares, compared to its average volume of 2,009,086. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business has a 50 day simple moving average of $144.27 and a 200-day simple moving average of $128.63. The stock has a market cap of $22.90 billion, a P/E ratio of -14.44 and a beta of 1.11. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business's revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business earned $0.33 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.